Physician profile
Christopher Joseph Romero
NPI 1063558435
$35,159.79
in general payments reported to CMS, 2019-2025
11 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.99 · 2022: $4,840 · 2023: $4,103 · 2024: $204 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $11K · Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,650.60 |
| Travel and Lodging | $10,762.82 |
| Food and Beverage | $843.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk Health Care Ag | $15,481.83 | 2025 | |
| Novo Nordisk INC | $11,764.63 | 2023-2025 | Sogroya, Norditropin |
| Ascendis Pharma Endocrinology INC | $4,691.84 | 2022 | |
| Pfizer INC. | $1,625.00 | 2025 | |
| Eton Pharmaceuticals, INC. | $1,208.33 | 2024-2025 | Alkindi, Increlex, Khindivi |
| Mml US, INC. | $148.48 | 2022 | |
| Biomarin Pharmaceutical INC. | $71.47 | 2025 | Voxzogo 1.2mg |
| Insulet Corporation | $62.99 | 2019 | |
| Dynasplint Systems INC. | $49.21 | 2025 | Dynasplint |
| Orchard Therapeutics North America | $37.92 | 2024 | Lenmeldy |
| Abbvie INC. | $18.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Romero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.